Sana Biotechnology, Inc. Files 2023 Annual Report on Form 10-K

Ticker: SANA · Form: 10-K · Filed: 2024-02-29T00:00:00.000Z

Sentiment: neutral

Topics: Sana Biotechnology, 10-K, Annual Report, Biotechnology, Financials

TL;DR

<b>Sana Biotechnology, Inc. has filed its 2023 annual report (10-K), detailing financial positions and business operations as of December 31, 2023.</b>

AI Summary

Sana Biotechnology, Inc. (SANA) filed a Annual Report (10-K) with the SEC on February 29, 2024. Sana Biotechnology, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing covers the period ending December 31, 2023, and was filed as of February 29, 2024. The company is incorporated in Delaware and operates in the Biological Products sector. Key financial data points such as fair value measurements, contingent consideration liabilities, and various asset/liability accounts are detailed for the fiscal year 2023. The report includes information on common stock, restricted stock, and employee stock options.

Why It Matters

For investors and stakeholders tracking Sana Biotechnology, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Sana Biotechnology's financial health, operational status, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The detailed financial disclosures, including fair value measurements and liabilities, offer insights into the company's valuation and risk exposure, enabling stakeholders to make informed investment decisions.

Risk Assessment

Risk Level: medium — Sana Biotechnology, Inc. shows moderate risk based on this filing. The company operates in the highly competitive and regulated biotechnology sector, facing risks related to research and development, clinical trials, and market adoption of its products, as indicated by the extensive financial and operational details in the 10-K.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Sana Biotechnology's current financial standing and potential future performance.

Key Numbers

Key Players & Entities

FAQ

When did Sana Biotechnology, Inc. file this 10-K?

Sana Biotechnology, Inc. filed this Annual Report (10-K) with the SEC on February 29, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Sana Biotechnology, Inc. (SANA).

Where can I read the original 10-K filing from Sana Biotechnology, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Sana Biotechnology, Inc..

What are the key takeaways from Sana Biotechnology, Inc.'s 10-K?

Sana Biotechnology, Inc. filed this 10-K on February 29, 2024. Key takeaways: Sana Biotechnology, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.. The filing covers the period ending December 31, 2023, and was filed as of February 29, 2024.. The company is incorporated in Delaware and operates in the Biological Products sector..

Is Sana Biotechnology, Inc. a risky investment based on this filing?

Based on this 10-K, Sana Biotechnology, Inc. presents a moderate-risk profile. The company operates in the highly competitive and regulated biotechnology sector, facing risks related to research and development, clinical trials, and market adoption of its products, as indicated by the extensive financial and operational details in the 10-K.

What should investors do after reading Sana Biotechnology, Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand Sana Biotechnology's current financial standing and potential future performance. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,457 words · 18 min read · ~15 pages · Grade level 16.7 · Accepted 2024-02-29 16:20:33

Key Financial Figures

Filing Documents

Business

Business 5 Item 1A.

Risk Factors

Risk Factors 72 Item 1B. Unresolved Staff Comments 144 Item 1C. Cybersecurity 144 Item 2.

Properties

Properties 145 Item 3.

Legal Proceedings

Legal Proceedings 145 Item 4. Mine Safety Disclosures 145 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 146 Item 6. [Reserved] 147 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 148 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 162 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 164 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 188 Item 9A.

Controls and Procedures

Controls and Procedures 188 Item 9B. Other Information 188 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 189 PART III Item 10. Directors, Executive Officers and Corporate Governance 190 Item 11.

Executive Compensation

Executive Compensation 190 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 190 Item 13. Certain Relationships and Related Transactions, and Director Independence 190 Item 14. Principal Accounting Fees and Services 190 PART IV Item 15. Exhibits and Financial Statement Schedules 191 Item 16 Form 10-K Summary 194 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (Annual Report) contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report could be deemed forward-looking statements, including those statements highlighted below. In some cases, you can identify these statements by forward-looking words such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," "would," or "will," the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, include, but are not limited to, statements about: our expectations regarding the potential market size and size of the potential patient populations for our product candidates and any future product candidates, if approved for commercial use; our clinical and regulatory development plans; our expectations with regard to our preclinical studies, clinical trials, and research and development programs, including the impact, timing, and availability of data from such studies and trials; the timing of commencement and advancement of future preclinical studies, clinical trials, and research and development programs; our ability to acquire, discover, and develop product candidates and timely advance them into and through clinical data readouts and successful completion of clinical trials; our expectations regarding the potential safety, efficacy, or clinical utility of our product

Business

Item 1. Business. Overview We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologic drugs to clinical practice. Key to making this vision a reality will be finding consistent and scalable means of manufacturing cell-based medicines, and we have invested significantly in our hypoimmune (HIP) platform technology, which we refer to as our HIP platform, with the twin goals of using allogeneic cells that evade immune detection in patients and that we can manufacture at scale. We are developing cell engineering programs to revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. We currently have four clinical trials that are ongoing, or that we expect to commence in the near-term, evaluating our product candidates, or product candidates developed using our technologies, across seven diseases in multiple therapeutic areas, including B-cell malignancies, B-cell-mediated autoimmune disease, and type 1 diabetes (T1D), as described below. ARDENT is an ongoing Phase 1 clinical trial evaluating SC291, our hypoimmune-modified CD19 targeted allogeneic chimeric antigen receptor (CAR) T program, in B-cell malignancies, including non-Hodgkin's lymphoma (NHL) and chronic lymphoblastic leukemia (CLL ) ; GLEAM is a Phase 1 clinical trial evaluating SC291 in patients with lupus nephritis (LN), extrarenal lupus (ERL), and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; VIVID is a Phase 1 clinical trial evaluating SC262, our hypoimmune-modified CD22 CAR T program, in patients with relapsed and/or refractory B-cell malignanc

View on Read The Filing